Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 7INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 183Breast Neoplasms 174Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 105Stomach Neoplasms 81Pancreatic Neoplasms 79Lung Neoplasms 79Prostatic Neoplasms 77Melanoma 68Neoplasm Metastasis 67Recurrence 66Leukemia, Myeloid, Acute 66Multiple Myeloma 64Ovarian Neoplasms 62Carcinoma, Hepatocellular 62Lymphoma 61Advanced Solid Tumor 61Advanced Solid Tumors 56Solid Tumor 50Uterine Cervical Neoplasms 48Lymphoma, Non-Hodgkin 48Glioblastoma 44Lymphoma, B-Cell 40Leukemia 39Colonic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Sarcoma 30

Interventions

sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Advanced Biliary Tract Cancer × Clear all
NCT05653180 2023-04-03

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Unknown
20 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡